{"nctId":"NCT00834080","briefTitle":"ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals","startDateStruct":{"date":"2009-03"},"conditions":["Opiate Dependence"],"count":38,"armGroups":[{"label":"Medisorb naltrexone 380 mg (VIVITROL)","type":"EXPERIMENTAL","interventionNames":["Drug: Medisorb naltrexone 380 mg"]}],"interventions":[{"name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL 380 mg","Naltrexone for extended-release injectable suspension"]}],"eligibilityModule":{"eligibilityCriteria":"Primary Inclusion Criteria:\n\n* Health care professional (eg, physician, osteopath, nurse, pharmacist)\n* 18 years of age or older\n* Enrolled or enrolling in an extended outpatient treatment program for opioid dependence\n* Women of childbearing potential must agree to use an approved method of contraception for the duration of the study\n\nPrimary Exclusion Criteria:\n\n* Pregnancy and/or lactation\n* Evidence of hepatic failure\n* Active hepatitis\n* Any psychiatric disorder that would compromise ability to complete study requirements\n* Recent history of suicidal ideation or attempt\n* Current dependence to any drugs other than prescription opioids or heroin, benzodiazepines, caffeine, marijuana, alcohol, or nicotine\n* Positive urine drug test or self-reported use of opioids, cocaine, or amphetamines at screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study.","description":"A TEAE is any adverse event (AE), whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["Nausea","Injection site pain","Anxiety","Headache","Upper respiratory tract infection"]}}}